Case Report: Ulcerative Colitis-related Spondyloarthritis Treated with Golimumab Until 27 Weeks of Gestation

Overview

Journal Obstet Med

Specialty Gynecology & Obstetrics

Date 2024 Nov 28

PMID 39605871

Authors

Ryuichi Okazaki

Ikkou Hirata

Hinako Ikegami

Ryou Rokutanda

Ryohkan Funakoshi

Affiliations

Soon will be listed here.

Abstract

Although tumor necrosis factor inhibitors are recommended for preventing flare-ups in pregnant women with ulcerative colitis (UC), studies on golimumab use during pregnancy are scant. Herein, we present a 39-year-old woman with UC and spondyloarthritis. The patient preferred treatment with a long dosing interval that minimally affects the working life of the patient. Golimumab, considering its long dosing interval, was prescribed after discussion with the patient, physician and pharmacists. Clinical remission was achieved during pregnancy, and the patient delivered a healthy baby. The vaccines were administered according to the vaccine schedule: during the first year after birth, there were neither infections caused by live vaccines nor diseases that the administered vaccines are meant to prevent. Overall, this case suggests that golimumab treatment during pregnancy may be compatible; however, further evaluations, including drug-level analysis, are needed.

References

Goulden B, Chua N, Parker E, Giles I . A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero. Rheumatology (Oxford). 2022; 61(10):3902-3906. DOI: 10.1093/rheumatology/keac141. View

Mahadevan U, Robinson C, Bernasko N, Boland B, Chambers C, Dubinsky M . Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group. Gastroenterology. 2019; 156(5):1508-1524. DOI: 10.1053/j.gastro.2018.12.022. View

Otero-Lobato M, Adeyemo A, Higley M, Lomax K, Geldhof A, Esslinger S . Exposure to golimumab during pregnancy: Results from the Company's global safety database. Pharmacol Res Perspect. 2024; 12(4):e1240. PMC: 11227047. DOI: 10.1002/prp2.1240. View

Hemperly A, Vande Casteele N . Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. Clin Pharmacokinet. 2018; 57(8):929-942. DOI: 10.1007/s40262-017-0627-0. View

Eworuke E, Panucci G, Goulding M, Neuner R, Toh S . Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. Pharmacoepidemiol Drug Saf. 2018; 28(3):296-304. DOI: 10.1002/pds.4695. View

Moriya K, Hara R, Tomooka F, Shimozato N, Nishimura N, Kawaratani H . Concurrent Ulcerative Colitis in a Pregnant Patient with Rheumatoid Arthritis. Intern Med. 2023; 63(3):385-391. PMC: 10901711. DOI: 10.2169/internalmedicine.1833-23. View

Romanowska-Prochnicka K, Felis-Giemza A, Olesinska M, Wojdasiewicz P, Paradowska-Gorycka A, Szukiewicz D . The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci. 2021; 22(6). PMC: 7998738. DOI: 10.3390/ijms22062922. View

Weisman M, Moreland L, Furst D, Weinblatt M, Keystone E, Paulus H . Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003; 25(6):1700-21. DOI: 10.1016/s0149-2918(03)80164-9. View

Itakura A, Shoji S, Shigeru A, Kotaro F, Junichi H, Hironobu H . Guidelines for obstetrical practice in Japan: Japan Society of Obstetrics and Gynecology and Japan Association of Obstetricians and Gynecologists 2020 edition. J Obstet Gynaecol Res. 2022; 49(1):5-53. DOI: 10.1111/jog.15438. View

10.

Benoit L, Mir O, Berveiller P . Treating Ulcerative Colitis During Pregnancy: Evidence of Materno-Fetal Transfer of Golimumab. J Crohns Colitis. 2018; 13(5):669-670. DOI: 10.1093/ecco-jcc/jjy192. View

11.

Fitzpatrick T, Alsager K, Sadarangani M, Pham-Huy A, Murguia-Favela L, Morris S . Immunological effects and safety of live rotavirus vaccination after antenatal exposure to immunomodulatory biologic agents: a prospective cohort study from the Canadian Immunization Research Network. Lancet Child Adolesc Health. 2023; 7(9):648-656. DOI: 10.1016/S2352-4642(23)00136-0. View

12.

Flamant M, Paul S, Roblin X . Golimumab for the treatment of ulcerative colitis. Expert Opin Biol Ther. 2017; 17(7):879-886. PMC: 5490638. DOI: 10.1080/14712598.2017.1327576. View

13.

Chen J, Lin R, Guo G, Wu W, Ke M, Ke C . Physiologically-Based Pharmacokinetic Modeling of Anti-Tumor Necrosis Factor Agents for Inflammatory Bowel Disease Patients to Predict the Withdrawal Time in Pregnancy and Vaccine Time in Infants. Clin Pharmacol Ther. 2023; 114(6):1254-1263. DOI: 10.1002/cpt.3031. View

14.

Dai F, Hu M, Zhang Y, Zhu R, Chen L, Li Z . TNF-/anti-TNF- drugs and its effect on pregnancy outcomes. Expert Rev Mol Med. 2022; 24:e26. PMC: 9884758. DOI: 10.1017/erm.2022.18. View

15.

Sammaritano L, Bermas B, Chakravarty E, Chambers C, Clowse M, Lockshin M . 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken). 2020; 72(4):461-488. DOI: 10.1002/acr.24130. View

16.

Shealy D, Cai A, Staquet K, Baker A, Lacy E, Johns L . Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α. MAbs. 2010; 2(4):428-39. PMC: 3180089. DOI: 10.4161/mabs.12304. View

17.

Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L . Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol. 2016; 116:7-12. DOI: 10.1016/j.jri.2016.04.284. View

18.

Luu M, Benzenine E, Doret M, Michiels C, Barkun A, Degand T . Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION). Am J Gastroenterol. 2018; 113(11):1669-1677. DOI: 10.1038/s41395-018-0176-7. View

19.

Tanski W, Dudek K, Adamowski T . Work Ability and Quality of Life in Patients with Rheumatoid Arthritis. Int J Environ Res Public Health. 2022; 19(20). PMC: 9603111. DOI: 10.3390/ijerph192013260. View

20.

Hirata I, Hanaoka S, Rokutanda R, Funakoshi R, Hayashi H . Shared decision-making practices and patient values in pharmacist outpatient care for rheumatic disease: A multiple correspondence analysis. J Pharm Pharm Sci. 2023; 26:11135. PMC: 9990622. DOI: 10.3389/jpps.2023.11135. View